AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
MIMEDX Q2 net sales $99 mln, up 13% YoY, raises 2025 growth expectations.
ByAinvest
Wednesday, Jul 30, 2025 4:08 pm ET1min read
• MIMEDX reports record Q2 2025 net sales of $99m, up 13% YoY. • GAAP net income and diluted EPS at $10m and $0.06, respectively. • Adjusted EBITDA reaches $24m, or 25% of net sales. • Company raises 2025 net sales growth expectations. • Management to host conference call on July 30, 2025.
MIMEDX (NASDAQ: MDXG) announced its record-breaking second-quarter 2025 financial results, reporting net sales of $99 million, a 13% year-over-year (YoY) increase. The company's GAAP net income reached $10 million, with diluted earnings per share (EPS) at $0.06. Adjusted EBITDA climbed to $24 million, representing 25% of net sales [1].The company's performance was driven by robust growth across both the Wound and Surgical product segments. Wound product sales grew by 12%, primarily due to the success of CELERA™ and EMERGE™ products. Surgical products saw a 15% increase, with notable contributions from AMNIOFIX®, AMNIOEFFECT®, and HELIOGEN™ [1].
MIMEDX's gross profit margin slightly decreased to 81% from 83% in the prior year, driven by production variances and changes in product mix. Selling, general, and administrative (SG&A) expenses increased to $64 million from $55 million, primarily due to higher sales commissions and legal costs. Research and development (R&D) expenses remained stable at $3 million [1].
The company ended the quarter with $119 million in cash, up $12 million from the previous quarter and $15 million from year-end 2024. Management raised its 2025 net sales growth expectations to the low double-digits and maintained Adjusted EBITDA margin projections above 20% [1].
MIMEDX will host a conference call on July 30, 2025, at 4:30 PM ET to discuss its second-quarter 2025 results. The call can be accessed using the following information: Webcast: Click here; U.S. Investors: 877-407-6184; International Investors: 201-389-0877; Conference ID: 13754722 [1].
References:
[1] https://www.stocktitan.net/news/MDXG/mimedx-announces-record-second-quarter-2025-operating-and-financial-l0zeywejhxru.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet